Matan C Dabora
Overview
Explore the profile of Matan C Dabora including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
555
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dougan M, Azizad M, Mocherla B, Gottlieb R, Chen P, Hebert C, et al.
Clin Infect Dis
. 2021 Oct;
75(1):e440-e449.
PMID: 34718468
Background: Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment. Methods: This...
2.
Boye K, Erdemir E, Zimmerman N, Reddy A, Benneyworth B, Dabora M, et al.
Diabetes Ther
. 2021 Jul;
12(8):2223-2239.
PMID: 34275115
Introduction: Diabetes has been identified as a high-risk comorbidity for COVID-19 hospitalization. We evaluated additional risk factors for COVID-19 hospitalization and in-hospital mortality in a nationwide US database. Methods: This...
3.
Dougan M, Nirula A, Azizad M, Mocherla B, Gottlieb R, Chen P, et al.
N Engl J Med
. 2021 Jul;
385(15):1382-1392.
PMID: 34260849
Background: Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and...
4.
Cohen M, Nirula A, Mulligan M, Novak R, Marovich M, Yen C, et al.
JAMA
. 2021 Jun;
326(1):46-55.
PMID: 34081073
Importance: Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks in their facilities. Bamlanivimab, a neutralizing monoclonal antibody against...
5.